A retrospective study to evaluate the predictive ability of a DNA methylation status-based diagnostic method for the sensitivity of anti-EGFR treatment for metastatic colorectal cancer

A retrospective study to evaluate the predictive ability of a DNA methylation status-based diagnostic method for the sensitivity of anti-EGFR treatment in metastatic colorectal cancer - Observational study on a method for predicting the efficacy of anti-EGFR treatment for colorectal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041205

Enrollment

150

Registered

2020-07-24

Start date

2020-06-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with colorectal cancer who failed standard primary and secondary treatment without anti-EGFR antibody drugs and were treated with anti-EGFR antibody drugs in combination with irinotecan on tertiary therapy.

Exclusion criteria

Exclusion criteria: Patients who received anti-EGFR antibodies in the first or second line of treatment. Cases in which the patient is unable to submit the required amount of tissue samples from the primary tumor for measurement of methylation status. Cases considered by the attending physician to be unsuitable for enrollment in this study.

Design outcomes

Primary

Measure	Time frame
PFS (Progression Free Survival)	—

Countries

Japan

Contacts

Public ContactKota Ouchi

Institute of Development, Aging and Cancer (IDAC) Department of Clinical Oncology

kota.ouchi.b3@tohoku.ac.jp+81-22-717-8543

Outcome results